Michelle L. O’Donoghue works in General / Preventive / Lipids affiliated with Brigham and Women's Hospital.
Michelle L. O'Donoghue, MD, MPH, is the McGillycuddy-Logue Distinguished Chair in Cardiology at Brigham and Women's Hospital and an Associate Professor of Medicine at Harvard Medical School. She is a Senior Investigator in the TIMI Study Group. Her research focuses on multicenter clinical trials in acute coronary syndromes, novel lipid and antiplatelet therapies, biomarkers, and heart disease in women.
240 pubs · 15,351 cites · h-index 59
MPH
Harvard School of Public Health
2009
MD
Columbia University College of Physicians and Surgeons
2002
Undergraduate
McGill University
1998
McGillycuddy-Logue Distinguished Chair in Cardiology and Associate Professor of Medicine
Brigham and Women's Hospital / Harvard Medical School · 2009 - Present
Senior Investigator
TIMI Study Group · 2005 - Present
Associate Physician, Cardiovascular Division
Brigham and Women's Hospital · 2009 - Present
Lipoproteins and Cardiovascular Health · Chandigarh University
In TYDAL-TIMI 78 trial (phase 2b), ANGPLT4 inhibition was effective at ⬇️ triglyceride levels & was not associated w/ more adverse events compared to placebo. Greater reductions in TGs were seen in pts w/ ⬆️ baseline TG levels.
New England Journal of MedicineO’Donoghue et al.
General / Preventive / Lipids · Brigham and Women's Hospital
Initial combination therapy facilitated lower and sustained LDL-C levels, whereas a statin-first approach relies on subsequent treatment intensification. In routine practice, where follow-up and treatment escalation may be inconsistent, initiating combination therapy could help patients achieve lower LDL-C levels sooner. Whether this translates into better clinical outcomes requires further study, but would be anticipated based on prior evidence.
CirculationO’Donoghue
Journal of the American Heart AssociationSaid et al.Original Research
CirculationO’DonoghueOriginal Research
JACCHaller et al.cohort
HF polygenic risk score was associated with incident heart failure; leaves open whether it improves clinical risk stratification or prevention.
JACCRodés‐Cabau et al.Original Research
Expert review highlights elevated bleeding and stroke risks in transcatheter aortic valve implantation, indicating the need for randomized antithrombotic trials.
JACCO’Donoghue et al.meta-analysis
Although elevated Lp(a) is associated with higher MACE risk overall in secondary prevention CAD, marked between-study heterogeneity and the lack of a significant association in cohorts with average LDL cholesterol <130 mg/dL cast doubt on the prognostic utility of routine Lp(a) screening when LDL cholesterol is well controlled.
General / Preventive / Lipids · Cleveland Clinic
We know from numerous studies, too many to mention, that women have different pharmacokinetics compared to men and women tend to have more side effects. There are lots of instances where drug dosing is different between men and women, and yet these trials are 70% done in men and the recommendation is always carte blanche for both.
Journal of the American College of CardiologyCho et al.
Cardiologist, Brigham and Women's Hospital · Brigham and Women's Hospital
The intent here was just to highlight that there is a fair amount of variability that is observed when serial Lp(a) values are obtained over what was a relatively short time frame. There is clinical relevance for looking at people with high values at baseline, because ultimately these are really the patients that we're going to be considering initially for some of these Lp(a)-lowering therapies.
Journal of the American College of CardiologyGaba et al.
This new framework has the potential to engage millions of younger adults in earlier preventive care. The guideline's principal innovation is less about lowering treatment thresholds than about expanding the population for whom conversations about long-term cardiovascular prevention become approp...
Journal of the American College of CardiologyO’Donoghue
Vascular Medicine · Brigham and Women's Hospital
Thrilled to share our recent JACC Journals State-of-the-Art Review on fibrinolytic therapies for different thromboembolic diseases. Grateful to the outstanding experts I had the privilege to learn from and collaborate with on this paper!
Journal of the American College of CardiologyRashedi et al.
EHJMarston et al.cohort
A polygenic risk score for atrial fibrillation provides independent and complementary predictive value for incident AF when added to clinical risk scores and NT-proBNP in patients with cardiovascular disease.
CirculationZimerman et al.Original Research
Socio-Environmental Systems ModelingQian et al.meta-analysis
Reassures clinicians on dietary omega-3 safety regarding AF; leaves open causal effects of high-dose supplementation.
JACCKang et al.RCT
Evolocumab attenuates the elevated risk of major adverse cardiovascular events in individuals with obesity and atherosclerotic cardiovascular disease.
JAMA CardiolZimerman et al.RCT
This secondary analysis of the OCEAN(a)-DOSE trial evaluates the impact of olpasiran on atherogenic lipoproteins.
CirculationMonguillon et al.cohort
Achieving LDL-C levels <40 mg/dL in patients with previous ischemic stroke is associated with a significantly lower risk of major adverse cardiovascular events and recurrent stroke without increasing hemorrhagic stroke risk.
European Journal of Preventive CardiologyZimerman et al.cohort
May aid ASCVD risk stratification; extends polygenic data but remains hypothesis-generating without trial validation.
EHJSaid et al.cohort
A PAD polygenic risk score independently predicts prevalent PAD and incident major adverse limb events in patients with cardiometabolic disease, though its incremental discriminative value over clinical risk factors is modest.
American Journal of EpidemiologyThiesmeier et al.Meta-Analysis
Analysis shows multiple imputation and bivariate meta-analysis can enhance precision in cardiovascular trials, retaining valuable information.
